Did You Know?

Editor’s Picks

Latest News

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1,...

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology ESTERO, FL / ACCESS...

vVARDIS Advances Sustainable, Drill-Free Caries Management Consistent With WHO’s Forward-Looking Vision for Environmentally Friendly Oral Health

ZUG, SWITZERLAND / ACCESS Newswire / January 22, 2026 / vVARDIS, a Swiss high-growth healthcare company welcomes the release of...

Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health

Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through...

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel...

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital Management (SR...

Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the...

error: Content is protected !!